The treatment of cognitive impairment in schizophrenia

Pharmacology Biochemistry and Behavior

Volumn 99, Issue 2, 2011, Pages 245-253

  Goff, Donald C ^a,c   Hill, Michele ^a   Barch, Deanna ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Freedom Trail Clinic   (United States)

Author keywords

Clinical trials; Cognition; Drug development; Pharmacology; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; BUSPIRONE; CLOZAPINE; CYCLOSERINE; DEXAMPHETAMINE; DEXTRO SERINE; DIHYDREXIDINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; FLUMAZENIL; HALOPERIDOL; KETAMINE; LAMOTRIGINE; LORAZEPAM; LY 354754; METABOTROPIC RECEPTOR AGONIST; MK 0777; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENCYCLIDINE; POMAGLUMETAD METHIONIL; PSYCHOSTIMULANT AGENT; SARCOSINE; SB 743457; SEROTONIN 6 ANTAGONIST; SILDENAFIL; TANDOSPIRONE; TOLCAPONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ARTICLE; CHOLINERGIC TRANSMISSION; COGNITION; COGNITIVE DEFECT; DOPAMINERGIC TRANSMISSION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; GABAERGIC TRANSMISSION; GLUTAMATERGIC TRANSMISSION; HUMAN; LIVER TOXICITY; MEMORY CONSOLIDATION; METHODOLOGY; NAUSEA; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; TREATMENT OUTCOME; WORKING MEMORY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; DOPAMINE; DOPAMINE AGENTS; EXCITATORY AMINO ACID AGENTS; GABA AGENTS; HUMANS; NOOTROPIC AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SEROTONIN AGENTS;

EID: 79958274304     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2010.11.009     Document Type: Article

References (152)

1. R.A. Adcock, C. Dale, M. Fisher, S. Aldebot, A. Genevsky, and G.V. Simpson When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia Schizophr Bull 35 2009 1132 1141
2. G.P. Amminger, M.R. Schafer, K. Papageorgiou, C.M. Klier, S.M. Cotton, and S.M. Harrigan Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial Arch Gen Psychiatry 67 2010 146 154
3. A. Anand, D.S. Charney, D.A. Oren, R.M. Berman, X.S. Hu, and A. Cappiello Attentuation of the neuropsychiatric effects of ketamine with lamotrigine Arch Gen Psychiatry 57 2000 270 276
4. J.A. Apud, V. Mattay, J. Chen, B.S. Kolachana, J.H. Callicott, and R. Rasetti Tolcapone improves cognition and cortical information processing in normal human subjects Neuropsychopharmacology 32 2007 1011 1020 (Pubitemid 46631983)
5. D.M. Barch, and C.S. Carter Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers Schizophr Res 77 2005 43 58 (Pubitemid 40957060)
6. D.M. Barch, V. Mitropoulou, P.D. Harvey, A.S. New, J.M. Silverman, and L.J. Siever Context-processing deficits in schizotypal personality disorder J Abnorm Psychol 113 2004 556 568 (Pubitemid 39431110)
7. R.S. Barr, M.A. Culhane, L.E. Jubelt, R.S. Mufti, M.A. Dyer, and A.P. Weiss The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls Neuropsychopharmacology 33 2008 480 490
8. M. Berk, D. Copolov, O. Dean, K. Lu, S. Jeavons, and I. Schapkaitz N-acetyl cysteine as a glutathione precursor for schizophrenia - a double-blind, randomized, placebo-controlled trial Biol Psychiatry 64 2008 361 368
9. M.D. Black Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data Psychopharmacology (Berl) 179 2005 154 163 (Pubitemid 40584805)
10. C.R. Breese, M.J. Lee, C.E. Adams, B. Sullivan, J. Logel, and K.M. Gillen Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia Neuropsychopharmacology 23 2000 351 364
11. R.W. Buchanan, M. Davis, D. Goff, M.F. Green, R.S. Keefe, and A.C. Leon A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia Schizophr Bull 31 2005 5 19 (Pubitemid 41214353)
12. R.W. Buchanan, D.C. Javitt, S.R. Marder, N.R. Schooler, J.M. Gold, and R.P. McMahon The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments Am J Psychiatry 164 2007 1593 1602 (Pubitemid 350069740)
13. R.W. Buchanan, R.R. Conley, D. Dickinson, M.P. Ball, S. Feldman, and J.M. Gold Galantamine for the treatment of cognitive impairments in people with schizophrenia Am J Psychiatry 165 2008 82 89 (Pubitemid 351704556)
14. Buchanan R.W.; Barch D.M.; Csernansky J.; Goff D.C.; Gold J.M.; and Jarskog F. MK-0777 for the treatment of cognitive impairments in people with schizophrenia Schizophr Res 117 2010 119
15. Buchanan R.W.; Keefe R.S.; Umbricht D.; Green M.F.; Laughren T.; and Marder S.R. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2010 Jul 13 [Epub ahead of print]
16. S.A. Castner, and P.S. Goldman-Rakic Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation J Neurosci 24 2004 1446 1450 (Pubitemid 38222996)
17. S.A. Castner, G.V. Williams, and P.S. Goldman-Rakic Reversal of working memory deficits by short-term dopamine D1 receptor stimulation Science 287 2000 2020 2022 (Pubitemid 30158679)
18. B. Cornblatt, M. Obuchowski, S. Roberts, S. Pollack, and L. Erlenmeyer-Kimling Cognitive and behavioral precursors of schizophrenia Dev Psychopathol 11 1999 487 508
19. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment Am J Psychiatry 158 2001 918 925 (Pubitemid 32547622)
20. D.G. Daniel, D.R. Weinberger, D.W. Jones, J.R. Zigun, R. Coppola, and S. Handel The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia J Neurosci 11 1991 1907 1917
21. K. Davis, R. Kahn, G. Ko, and M. Davidson Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1991 1474 1486
22. M. Davis, K. Ressler, B.O. Rothbaum, and R. Richardson Effects of d-cycloserine on extinction: translation from preclinical to clinical work Biol Psychiatry 60 2006 369 375 (Pubitemid 44215855)
23. B. Dean, M. McLeod, D. Keriakous, J. McKenzie, and E. Scarr Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia Mol Psychiatry 7 2002 1083 1091 (Pubitemid 36044267)
24. Delawalla Z.; Barch D.M.; Fisher Eastep J.L.; Thomason E.S.; Hanewinkel M.J.; and Thompson P.A. Factors mediating cognitive deficits and psychopathology among siblings of individuals with schizophrenia Schizophr Bull 32 2006 525 537 (Pubitemid 43992326)
25. C.C. Dickey, R.W. McCarley, M.A. Niznikiewicz, M.M. Voglmaier, L.J. Seidman, and S. Kim Clinical, cognitive, and social characteristics of a sample of neuroleptic-naive persons with schizotypal personality disorder Schizophr Res 78 2005 297 308 (Pubitemid 41254031)
26. D. Dickinson, W. Tenhula, S. Morris, C. Brown, J. Peer, and K. Spencer A randomized, controlled trial of computer-assisted cognitive remediation for schizophrenia Am J Psychiatry 167 2010 170 180
27. L.B. Dixon, F. Dickerson, A.S. Bellack, M. Bennett, D. Dickinson, and R.W. Goldberg The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements Schizophr Bull 36 2010 48 70
28. K.A. Dorph-Petersen, J.N. Pierri, J.M. Perel, Z. Sun, A.R. Sampson, and D.A. Lewis The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys Neuropsychopharmacology 30 2005 1649 1661 (Pubitemid 43086022)
29. S.M. Dravid, P.B. Burger, A. Prakash, M.T. Geballe, R. Yadav, and P. Le Structural determinants of d-cycloserine efficacy at the NR1/NR2C NMDA receptors J Neurosci 30 2010 2741 2754
30. M.A. Dyer, O. Freudenreich, M.A. Culhane, G.N. Pachas, T. Deckersbach, and E. Murphy High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia Schizophr Res 102 2008 88 95
31. S.M. Eack, D.P. Greenwald, S.S. Hogarty, S.J. Cooley, A.L. DiBarry, and D.M. Montrose Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial Psychiatr Serv 60 2009 1468 1476
32. Eack S.M.; Hogarty G.E.; Cho R.Y.; Prasad K.M.; Greenwald D.P.; and Hogarty S.S. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial Arch Gen Psychiatry 67 2010 674 682
33. M.F. Egan, T.E. Goldberg, B.S. Kolachana, J.H. Callicott, C.M. Mazzanti, and R.E. Straub Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia Proc Natl Acad Sci USA 98 2001 6917 6922 (Pubitemid 32538317)
34. el-Mallakh R.S.; Kirch D.G.; Shelton R.; Fan K.J.; Pezeshkpour G.; and Kanhouwa S. The nucleus basalis of Meynert, senile plaques, and intellectual impairment in schizophrenia J Neuropsychiatry Clin Neurosci 3 1991 383 386
35. B. Fagerlund, B. Soholm, A. Fink-Jensen, H. Lublin, and B.Y. Glenthoj Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study Clin Neuropharmacol 30 2007 3 12 (Pubitemid 46204312)
36. M. Fisher, C. Holland, M.M. Merzenich, and S. Vinogradov Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia Am J Psychiatry 166 2009 805 811
37. R. Freedman, M. Hall, L.E. Adler, and S. Leonard Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia Biol Psychiatry 38 1995 22 33
38. R. Freedman, A. Olincy, R.W. Buchanan, J.G. Harris, J.M. Gold, and L. Johnson Initial phase 2 trial of a nicotinic agonist in schizophrenia Am J Psychiatry 165 2008 1040 1047
39. Freudenreich O.; Herz L.; Deckersbach T.; Evins A.E.; Henderson D.C.; and Cather C. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial Psychopharmacology (Berl) 181 2005 358 363 (Pubitemid 41492206)
40. O. Freudenreich, D.C. Henderson, E.A. Macklin, A.E. Evins, X. Fan, and C. Cather Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial J Clin Psychiatry 70 2009 1674 1680
41. J.I. Friedman Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists Psychopharmacology (Berl) 174 2004 45 53 (Pubitemid 38925090)
42. J.I. Friedman, D.N. Adler, E. Howanitz, P.D. Harvey, G. Brenner, and H. Temporini A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia Biol Psychiatry 51 2002 349 357 (Pubitemid 34251171)
43. M.L. Furey, P. Pietrini, G.E. Alexander, M.B. Schapiro, and B. Horwitz Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans Brain Res Bull 51 2000 213 218 (Pubitemid 30077486)
44. M.S. George, C.E. Molnar, E.L. Grenesko, B. Anderson, Q. Mu, and K. Johnson A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia Schizophr Res 93 2007 42 50 (Pubitemid 46817947)
45. D.C. Glahn, S. Therman, M. Manninen, M. Huttunen, J. Kaprio, and J. Lonnqvist Spatial working memory as an endophenotype for schizophrenia Biol Psychiatry 53 2003 624 626 (Pubitemid 36385065)
46. D.C. Goff Pharmacologic implications of neurobiological models of schizophrenia Harv Rev Psychiatry 13 2005 352 359 (Pubitemid 43050920)
47. D.C. Goff, and J.T. Coyle The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry 158 2001 1367 1377 (Pubitemid 32847232)
48. D.C. Goff, D.C. Henderson, and E. Amico Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects Am J Psychiatry 149 1992 1189 1194
49. D. Goff, G. Tsai, J. Levitt, E. Amico, D. Manoach, and D. Schoenfeld A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia Arch Gen Psychiatry 56 1999 21 27 (Pubitemid 29055046)
50. D. Goff, L. Leahy, I. Berman, T. Posever, L. Herz, and A. Leon A placebo-controlled pilot study of the ampakine, CX516, added to clozapine in schizophrenia J Clin Psychopharmacol 21 2001 484 487 (Pubitemid 32937430)
51. D.C. Goff, L. Herz, T. Posever, V. Shih, G. Tsai, and D.C. Henderson A six-month, placebo-controlled trial of D: -cycloserine co-administered with conventional antipsychotics in schizophrenia patients Psychopharmacology (Berl) 179 2005 144 150 (Pubitemid 40576701)
52. D.C. Goff, R. Keefe, L. Citrome, K. Davy, J.H. Krystal, and C. Large Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials J Clin Psychopharmacol 27 2007 582 589 (Pubitemid 351339444)
53. D.C. Goff, C. Cather, J.D. Gottlieb, A.E. Evins, J. Walsh, and L. Raeke Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study Schizophr Res 106 2008 320 327
54. D.C. Goff, J.S. Lamberti, A.C. Leon, M.F. Green, A.L. Miller, and J. Patel A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 33 2008 465 472
55. D.C. Goff, C. Cather, O. Freudenreich, D.C. Henderson, A.E. Evins, and M.A. Culhane A placebo-controlled study of sildenafil effects on cognition in schizophrenia Psychopharmacology (Berl) 202 2009 411 417
56. P.E. Gold Coordination of multiple memory systems Neurobiol Learn Mem 82 2004 230 242 (Pubitemid 39298718)
57. J.M. Gold, R.W. Goldberg, S.W. McNary, L.B. Dixon, and A.F. Lehman Cognitive correlates of job tenure among patients with severe mental illness Am J Psychiatry 159 2002 1395 1402 (Pubitemid 34832723)
58. T.E. Goldberg, L.B. Bigelow, D.R. Weinberger, D.G. Daniel, and J.E. Kleinman Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia Am J Psychiatry 148 1991 78 84
59. P.S. Goldman-Rakic, S.A. Castner, T.H. Svensson, L.J. Siever, and G.V. Williams Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction Psychopharmacology (Berl) 174 2004 3 16 (Pubitemid 38925085)
60. Green M.F.; Kern R.S.; Braff D.L.; and JM Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull 26 2000 119 136 (Pubitemid 30317696)
61. M.F. Green, R.S. Kern, and R.K. Heaton Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS Schizophr Res 72 2004 41 51 (Pubitemid 39452904)
62. R.E. Hampson, G. Rogers, G. Lynch, and S. Deadwyler Facilitative effects of the Ampakine CX516 on short term memory in rats: correlations with hippocampal neuronal activity J Neurosci 18 1998 2748 2763 (Pubitemid 28141820)
63. M.E. Hasselmo, and J.M. Bower Acetylcholine and memory Trends Neurosci 16 1993 218 222 (Pubitemid 23139185)
64. R. Heaton, J.A. Gladsjo, B.W. Palmer, J. Kuck, T.D. Marcotte, and D.V. Jeste Stability and course of neuropsychological deficits in schizophrenia Arch Gen Psychiatry 58 2001 24 32 (Pubitemid 32057762)
65. Heckers S. Neuroimaging studies of the hippocampus in schizophrenia Hippocampus 2001 520 528 (Pubitemid 33100373)
66. M.D. Hunter, V. Ganesan, I.D. Wilkinson, and S.A. Spence Impact of modafinil on prefrontal executive function in schizophrenia Am J Psychiatry 163 2006 2184 2186 (Pubitemid 46114242)
67. J. Ichikawa, J. Dai, I.A. O'Laughlin, W.L. Fowler, and H.Y. Meltzer Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325 339 (Pubitemid 34159210)
68. F. Irani, S. Kalkstein, E.A. Moberg, and P.J. Moberg Neuropsychological Performance in Older Patients With Schizophrenia: A Meta-Analysis of Cross-sectional and Longitudinal Studies Schizophr Bull 2010
69. L.K. Jacobsen, D.C. D'Souza, W.E. Mencl, K.R. Pugh, P. Skudlarski, and J.H. Krystal Nicotine effects on brain function and functional connectivity in schizophrenia Biol Psychiatry 55 2004 850 858 (Pubitemid 38429877)
70. Javitt, DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984 - 997, 979. (Pubitemid 39524288)
71. D.C. Javitt Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification Curr Opin Drug Discov Dev 12 2009 468 478
72. D.C. Javitt Effects of intranasal AL-108 (Davunetide) on neurocognition and functional outcome in schizophrenia Schizophr Res 119 2010 118 119
73. D. Javitt, and S. Zukin Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 148 1991 1301 1308
74. J. Jentsch, and R. Roth The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 20 1999 201 225 (Pubitemid 29067401)
75. C.N. Johnson, M. Ahmed, and N.D. Miller 5-HT6 receptor antagonists: prospects for the treatment of cognitive disorders including dementia Curr Opin Drug Discov Dev 11 2008 642 654
76. L.E. Jubelt, R.S. Barr, D.C. Goff, T. Logvinenko, A.P. Weiss, and A.E. Evins Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia Psychopharmacology (Berl) 199 2008 89 98
77. Kane J.M.; D'Souza D.C.; Patkar A.A.; Youakim J.M.; Tiller J.M.; and Yang R. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study J Clin Psychiatry 71 2010 1475 1481
78. J.T. Kantrowitz, D. Malhotra, B. Cornblatt, G. Silipo, A. Balla, and R.F. Suckow High dose d-serine in the treatment of schizophrenia Schizophr Res 121 2010 125 130
79. R.S. Keefe Should cognitive impairment be included in the diagnostic criteria for schizophrenia? World Psychiatry 7 2008 22 28 (Pubitemid 351338182)
80. R.S. Keefe, R.M. Bilder, S.M. Davis, P.D. Harvey, B.W. Palmer, and J.M. Gold Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch Gen Psychiatry 64 2007 633 647 (Pubitemid 46878665)
81. R.S. Keefe, A.K. Malhotra, H.Y. Meltzer, J.M. Kane, R.W. Buchanan, and A. Murthy Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial Neuropsychopharmacology 33 2008 1217 1228 (Pubitemid 351521707)
82. L.S. Kegeles, A. Abi-Dargham, Y. Zea-Ponce, J. Rodenhiser, J.J. Mann, and R. Van Heertum Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia Biol Psychiatry 48 2000 627 640
83. K. Koike, K. Hashimoto, N. Takai, E. Shimizu, N. Komatsu, and H. Watanabe Tropisetron improves deficits in auditory P50 suppression in schizophrenia Schizophr Res 76 2005 67 72 (Pubitemid 40824561)
84. G.T. Konopaske, K.A. Dorph-Petersen, J.N. Pierri, Q. Wu, A.R. Sampson, and D.A. Lewis Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys Neuropsychopharmacology 32 2007 1216 1223 (Pubitemid 46788845)
85. J.H. Krystal, W. Abi-Saab, E. Perry, D.C. D'Souza, N. Liu, and R. Gueorguieva Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects Psychopharmacology (Berl) 179 2005 303 309 (Pubitemid 40576718)
86. W. Laan, D.E. Grobbee, J.P. Selten, C.J. Heijnen, R.S. Kahn, and H. Burger Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial J Clin Psychiatry 71 2010 520 527
87. Lane H.Y.; Lin C.H.; Huang Y.J.; Liao C.H.; Chang Y.C.; and Tsai G.E. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and d-serine add-on treatment for schizophrenia Int J Neuropsychopharmacol 2009 1 10
88. M. Laruelle, and A. Abi-Dargham Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies J Psychopharmacol 13 1999 358 371 (Pubitemid 30055180)
89. S.W. Lee, J.G. Lee, B.J. Lee, and Y.H. Kim A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia Int Clin Psychopharmacol 22 2007 63 68
90. S. Leonard, J. Gault, J. Hopkins, J. Logel, R. Vianzon, and M. Short Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia Arch Gen Psychiatry 59 2002 1085 1096 (Pubitemid 35424018)
91. D.A. Lewis, D.W. Volk, and T. Hashimoto Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction Psychopharmacology (Berl) 174 2004 143 150 (Pubitemid 38925099)
92. D.A. Lewis, R.Y. Cho, C.S. Carter, K. Eklund, S. Forster, and M.A. Kelly Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia Am J Psychiatry 165 2008 1585 1593
93. J.A. Lieberman, K. Papadakis, J. Csernansky, R. Litman, J. Volavka, and X.D. Jia A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia Neuropsychopharmacology 34 2009 1322 1329
94. J.E. Lisman, J.T. Coyle, R.W. Green, D.C. Javitt, F.M. Benes, and S. Heckers Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia Trends Neurosci 31 2008 234 242
95. C.E. Marx, R.S. Keefe, R.W. Buchanan, R.M. Hamer, J.D. Kilts, and D.W. Bradford Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia Neuropsychopharmacology 34 2009 1885 1903
96. V.S. Mattay, J.H. Callicott, A. Bertolino, I. Heaton, J.A. Frank, and R. Coppola Effects of dextroamphetamine on cognitive performance and cortical activation Neuroimage 12 2000 268 275
97. V.S. Mattay, T.E. Goldberg, F. Fera, A.R. Hariri, A. Tessitore, and M.F. Egan Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine Proc Natl Acad Sci USA 100 2003 6186 6191 (Pubitemid 36576952)
98. S.R. McGurk, E.W. Twamley, D.I. Sitzer, G.J. McHugo, and K.T. Mueser A meta-analysis of cognitive remediation in schizophrenia Am J Psychiatry 164 2007 1791 1802 (Pubitemid 351739231)
99. L. Menzies, C. Ooi, S. Kamath, J. Suckling, P. McKenna, and P. Fletcher Effects of gamma-aminobutyric acid-modulating drugs on working memory and brain function in patients with schizophrenia Arch Gen Psychiatry 64 2007 156 167 (Pubitemid 46220773)
100. M.J. Minzenberg, and C.S. Carter Modafinil: a review of neurochemical actions and effects on cognition Neuropsychopharmacology 33 2008 1477 1502 (Pubitemid 351684703)
101. M.J. Minzenberg, J.H. Poole, C. Benton, and S. Vinogradov Association of anticholinergic load with impairment of complex attention and memory in schizophrenia Am J Psychiatry 161 2004 116 124 (Pubitemid 38419316)
102. M.J. Minzenberg, A.J. Watrous, J.H. Yoon, S. Ursu, and C.S. Carter Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional MRI Science 322 2008 1700 1702
103. M.J. Minzenberg, A.R. Laird, S. Thelen, C.S. Carter, and D.C. Glahn Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia Arch Gen Psychiatry 66 2009 811 822
104. B. Moghaddam, and B. Adams Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist Science 281 1998 1349 1352 (Pubitemid 28406826)
105. Q. Mu, K. Johnson, P.S. Morgan, E.L. Grenesko, C.E. Molnar, and B. Anderson A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia Schizophr Res 94 2007 332 341 (Pubitemid 47039290)
106. N. Muller, D. Krause, S. Dehning, R. Musil, R. Schennach-Wolff, and M. Obermeier Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment Schizophr Res 121 2010 118 124
107. C.S. Myers, O. Robles, A.N. Kakoyannis, J.D. Sherr, M.T. Avila, and T.A. Blaxton Nicotine improves delayed recognition in schizophrenic patients Psychopharmacology (Berl) 174 2004 334 340 (Pubitemid 39044291)
108. T.A. Niendam, C.E. Bearden, I.M. Rosso, L.E. Sanchez, T. Hadley, and K.H. Nuechterlein A prospective study of childhood neurocognitive functioning in schizophrenic patients and their siblings Am J Psychiatry 160 2003 2060 2062 (Pubitemid 39619649)
109. Y. Nong, Y.Q. Huang, W. Ju, L.V. Kalia, G. Ahmadian, and Y.T. Wang Glycine binding primes NMDA receptor internalization Nature 422 2003 302 307 (Pubitemid 36378356)
110. K. Nuechterlein, and M.F. Green MATRICS Consensus Cognitive Battery (MCCB) 2006 MATRICS Assessments, Inc. Los Angeles
111. A. Olincy, J.G. Harris, L.L. Johnson, V. Pender, S. Kongs, and D. Allensworth Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia Arch Gen Psychiatry 63 2006 630 638 (Pubitemid 43848294)
112. F.G. Pajonk, T. Wobrock, O. Gruber, H. Scherk, D. Berner, and I. Kaizl Hippocampal plasticity in response to exercise in schizophrenia Arch Gen Psychiatry 67 2010 133 143
113. R. Palacios-Pelaez, W.J. Lukiw, and N.G. Bazan Omega-3 essential fatty acids modulate initiation and progression of neurodegenerative disease Mol Neurobiol 41 2010 367 374
114. A.S. Parnas, M. Weber, and R. Richardson Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats Neurobiol Learn Mem 83 2005 224 231 (Pubitemid 40488810)
115. S.T. Patil, L. Zhang, F. Martenyi, S.L. Lowe, K.A. Jackson, and B.V. Andreev Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial Nat Med 13 2007 1102 1107 (Pubitemid 47517511)
116. T.L. Patterson, S. Goldman, C.L. McKibbin, T. Hughs, and D.V. Jeste UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults Schizophr Bull 27 2001 235 245 (Pubitemid 33644299)
117. J.M. Pierre, J.H. Peloian, D.A. Wirshing, W.C. Wirshing, and S.R. Marder A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia J Clin Psychiatry 68 2007 705 710 (Pubitemid 46841853)
118. R.H. Pietrzak, P.J. Snyder, and P. Maruff Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia Hum Psychopharmacol 25 2010 353 358
119. M.C. Potter, G.I. Elmer, R. Bergeron, E.X. Albuquerque, P. Guidetti, and H.Q. Wu Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior Neuropsychopharmacology 35 2010 1734 1742
120. P. Powchik, M. Davidson, V. Haroutunian, S.M. Gabriel, D.P. Purohit, and D.P. Perl Postmortem studies in schizophrenia Schizophr Bull 24 1998 325 341 (Pubitemid 28378220)
121. M. Poyurovsky, D. Koren, I. Gonopolsky, M. Schneidman, C. Fuchs, and A. Weizman Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study Eur Neuropsychopharmacol 13 2003 123 128 (Pubitemid 36313287)
122. T.J. Raedler, M.B. Knable, D.W. Jones, R.A. Urbina, J.G. Gorey, and K.S. Lee In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia Am J Psychiatry 160 2003 118 127 (Pubitemid 36042435)
123. A. Reichenberg, and P.D. Harvey Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings Psychol Bull 133 2007 833 858
124. O.A. Reneerkens, K. Rutten, H.W. Steinbusch, A. Blokland, and J. Prickaerts Selective phosphodiesterase inhibitors: a promising target for cognition enhancement Psychopharmacology (Berl) 202 2009 419 443
125. Ritsner M.S.; Gibel A.; Shleifer T.; Boguslavsky I.; Zayed A.; and Maayan R. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial J Clin Psychiatry 71 2010 1351 1362
126. B.L. Roth, S.M. Hanizavareh, and A.E. Blum Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology (Berl) 174 2004 17 24 (Pubitemid 38925086)
127. L.E. Schechter, L.A. Dawson, and J.A. Harder The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease Curr Pharm Des 8 2002 139 145 (Pubitemid 34449897)
128. C. Schlumberger, M. Pietraszek, A. Gravius, and W. Danysz Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia Pharmacol Biochem Behav 95 2009 23 30
129. M.H. Schubert, K.A. Young, and P.B. Hicks Galantamine improves cognition in schizophrenic patients stabilized on risperidone Biol Psychiatry 60 2006 530 533 (Pubitemid 44402376)
130. S. Sevy, M.H. Rosenthal, J. Alvir, S. Meyer, H. Visweswaraiah, and H. Gunduz-Bruce Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications J Clin Psychiatry 66 2005 839 843 (Pubitemid 41032824)
131. A. Shekhar, W.Z. Potter, J. Lightfoot, J. Lienemann, S. Dube, and C. Mallinckrodt Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia Am J Psychiatry 165 2008 1033 1039
132. A. Shiina, Y. Shirayama, T. Niitsu, T. Hashimoto, T. Yoshida, and T. Hasegawa A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia Ann Gen Psychiatry 9 2010 27
133. B.E. Snitz, A.W. Macdonald III, and C.S. Carter Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes Schizophr Bull 32 2006 179 194 (Pubitemid 43063833)
134. H.J. Sorensen, E.L. Mortensen, J. Parnas, and S.A. Mednick Premorbid neurocognitive functioning in schizophrenia spectrum disorder Schizophr Bull 32 2006 578 583 (Pubitemid 43992331)
135. S.A. Spence, R.D. Green, I.D. Wilkinson, and M.D. Hunter Modafinil modulates anterior cingulate function in chronic schizophrenia Br J Psychiatry 187 2005 55 61 (Pubitemid 41002514)
136. U. Staubli, G. Rogers, and G. Lynch Facilitation of glutamate receptors enhances memory Proc Natl Acad Sci USA 91 1994 777 781 (Pubitemid 24041485)
137. T. Sumiyoshi, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, and C. Sumiyoshi Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment Am J Psychiatry 158 2001 1722 1725 (Pubitemid 32923670)
138. T. Sumiyoshi, S. Park, K. Jayathilake, A. Roy, A. Ertugrul, and H.Y. Meltzer Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study Schizophr Res 95 2007 158 168 (Pubitemid 47313647)
139. A.V. Terry Jr.; J.J. Buccafusco, and C. Wilson Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets Behav Brain Res 195 2008 30 38
140. D.R. Thomas, A. Dada, G.A. Jones, R.A. Deisz, S. Gigout, and C.J. Langmead N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor Neuropharmacology 58 2010 1206 1214
141. G. Tsai, H.Y. Lane, P. Yang, M.Y. Chong, and N. Lange Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 55 2004 452 456 (Pubitemid 38338531)
142. Tugal O.; Yazici K.M.; Anil Yagcioglu A.E.; and Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive
143. H.J. Tuominen, J. Tiihonen, and K. Wahlbeck Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis Schizophr Res 72 2005 225 234 (Pubitemid 39550993)
144. D.C. Turner, L. Clark, E. Pomarol-Clotet, P. McKenna, T.W. Robbins, and B.J. Sahakian Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia Neuropsychopharmacology 29 2004 1363 1373 (Pubitemid 38780659)
145. A. Tuulio-Henriksson, R. Arajarvi, T. Partonen, J. Haukka, T. Varilo, and M. Schreck Familial loading associates with impairment in visual span among healthy siblings of schizophrenia patients Biol Psychiatry 54 2003 623 628 (Pubitemid 41115099)
146. N. Upton, T.T. Chuang, A.J. Hunter, and D.J. Virley 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease Neurotherapeutics 5 2008 458 469 (Pubitemid 351952494)
147. J.M. Uslaner, S. Parmentier-Batteur, R.B. Flick, N.O. Surles, J.S. Lam, and C.H. McNaughton Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus Neuropharmacology 57 2009 531 538
148. S. Vinogradov, M. Fisher, C. Holland, W. Shelly, O. Wolkowitz, and S.H. Mellon Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol Psychiatry 66 2009 549 553
149. B. Vitiello, A. Martin, J. Hill, C. Mack, S. Molchan, and R. Martinez Cognitive and behavioral effects of cholinergic, dopaminergic, and serotonergic blockade in humans Neuropsychopharmacology 16 1997 15 24 (Pubitemid 27030992)
150. M.M. Voglmaier, L.J. Seidman, M.A. Niznikiewicz, C.C. Dickey, M.E. Shenton, and R.W. McCarley Verbal and nonverbal neuropsychological test performance in subjects with schizotypal personality disorder Am J Psychiatry 157 2000 787 793 (Pubitemid 30249659)
151. K. Wojtal, M.K. Trojnar, and S.J. Czuczwar Endogenous neuroprotective factors: neurosteroids Pharmacol Rep 58 2006 335 340 (Pubitemid 44111068)
152. Wustenberg T.; Begemann M.; Bartels C.; Gefeller O.; Stawicki S.; and Hinze-Selch D. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia Mol Psychiatry 2010 May 18 [Epub ahead of print]